Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cosentyx under the microscope: new study tracks Real-World safety for skin and joint patients

NCT ID NCT07243782

First seen Dec 17, 2025 · Last updated May 22, 2026 · Updated 27 times

Summary

This study monitors the safety and effectiveness of the drug Cosentyx in Korean patients with three conditions: hidradenitis suppurativa (painful skin boils), pediatric plaque psoriasis (scaly skin patches in children), and juvenile idiopathic arthritis (childhood arthritis). About 76 participants will be followed during routine treatment. The main goal is to track side effects, while also measuring how well the drug controls symptoms like skin lesions and joint pain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06973, South Korea

Conditions

Explore the condition pages connected to this study.